Breast Cancer | Specialty

The OncLive Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

NCCN Guidelines Endorse FES PET for Workup of Recurrent/Metastatic ER+ Breast Cancer

May 25th 2023

The National Comprehensive Cancer Network Guidelines now recommend the use of 18F-Fluorestradiol positron emission tomography in certain circumstances during the systemic staging workup for patients with recurrent or metastatic for estrogen receptor–positive breast cancer.

Ribociclib/Fulvestrant Combo Generates PFS Improvement in Metastatic Breast Cancer

May 23rd 2023

Ribociclib plus switch endocrine therapy induced a statistically significant progression-free survival benefit compared with placebo plus switch endocrine therapy in patients with hormone receptor–positive, HER2-negative, metastatic breast cancer.

China’s NMPA Accepts sNDA for Toripalimab Plus Chemo in Advanced TNBC

May 23rd 2023

The National Medical Products Administration has accepted the supplemental new drug application seeking the approval of toripalimab in combination with nab-paclitaxel in patients with untreated metastatic or recurrent triple-negative breast cancer and a PD-L1 combined positive score of at least 1.

FDA Grants Priority Review to Lumisight Optical Imaging Agent for Breast Cancer Detection

May 23rd 2023

The FDA has granted priority review to a new drug application seeking the approval of the optical imaging agent Lumisight for use in patients with breast cancer, according to an announcement from Lumicell, Inc.

OncLive Honors 12 Cancer Care Pioneers

May 22nd 2023

For the 11th consecutive year, OncLive is honored to recognize oncology leaders whose innovations have contributed to immeasurable improvements in outcomes for countless patients.

Role of T-DXd in Patients With HER2+ Metastatic Breast Cancer and CNS Metastasis

May 22nd 2023

A brief discussion on the role of trastuzumab deruxtecan (T-DXd) in patients with HER2+ metastatic breast cancer who progress on tucatinib therapy.

HER2+ Metastatic Breast Cancer: Factors in Selecting 2L Therapy and Beyond

May 22nd 2023

A key opinion leader in HER2+ metastatic breast cancer shares his perspective on key factors in selecting second or later-line therapy.

Adjuvant Abemaciclib Provides Survival Benefit in Chinese Breast Cancer Population

May 18th 2023

Abemaciclib plus endocrine therapy delivered sustained survival benefits with a tolerable safety profile when used as adjuvant treatment in Chinese patients with high-risk, hormone receptor–positive, HER2-negative early breast cancer.

Elacestrant Highlights Promise of Oral SERDs in HR+/HER2– Metastatic Breast Cancer

May 18th 2023

Antoinette R. Tan, MD, MHSc, discussed the promise of oral SERDs as they continue to be developed for the treatment of patients with ER-positive, HER2-negative breast cancer, factors that inform treatment decisions following disease progression on a CDK4/6 inhibitor, and the growing role of antibody-drug conjugates across the breast cancer spectrum.

Dr Mina on the Evolution of T-DM1 and T-DXd in HER2+ Breast Cancer

May 17th 2023

Lida A. Mina, MD, discusses the evolution of the antibody-drug conjugates fam-trastuzumab deruxtecan-nxki and ado-trastuzumab emtansine in HER2-positive breast cancer.

Genomic Testing Is Critical for Improved Personalized Medicine and Treatment Sequencing in Breast Cancer

May 17th 2023

Lida A. Mina, MD, discusses the evolving role of ADCs across breast cancer subtypes, current data on the use of CDK4/6 inhibitors in HR-positive, HER2-negative breast cancer, and the increased use of genomic testing and NGS to improve the sequencing of agents in triple-negative breast cancer.

Initial Care in High-Volume Facilities Improves Survival for Patients With Breast Cancer

May 16th 2023

A statewide policy intervention that discouraged initial breast cancer surgical care for patients with Medicaid insurance in low-volume facilities led to a survival benefit.

Capivasertib Plus Fulvestrant Provides Consistent PFS Benefit in HR+ Advanced Breast Cancer, Across Key Subgroups

May 15th 2023

Capivasertib plus fulvestrant provided a clinically meaningful improvement in progression-free survival over fulvestrant alone in patients with hormone receptor–positive advanced breast cancer, including those who previously received a CDK4/6 inhibitor, chemotherapy in the advanced setting, or had baseline liver metastases.

HER2+ Metastatic Breast Cancer: An Evolving Treatment Armamentarium

May 15th 2023

Comprehensive insight on the treatment armamentarium currently available to patients with HER2+ metastatic breast cancer and CNS disease.

Landscape of HER2+ Metastatic Breast Cancer: Patient Overview

May 15th 2023

Expert oncologist Kevin Kalinsky, MD, MS, reviews a patient case of HER2+ metastatic breast cancer and highlights key findings in this disease setting.

OP-1250 Plus Palbociclib Demonstrates Activity, Safety in HR+/HER2– Metastatic Breast Cancer

May 14th 2023

The combination of OP-1250 and palbociclib produced a tolerable safety profile and elicited tumor responses and disease stabilization in patients with hormone receptor–positive, HER2-negative metastatic breast cancer.

MONALEESA-2 Subgroup Analysis Highlights Survival Benefit With Ribociclib/Letrozole in HR+ Breast Cancer

May 13th 2023

The frontline combination of ribociclib and letrozole significantly prolonged overall survival over letrozole alone in a subset of patients with hormone receptor–positive, HER2-negative advanced breast cancer who had de novo metastatic disease or late recurrence from neoadjuvant therapy, according to data from an exploratory analysis of the phase 3 MONALEESA-2 trial.

Neoadjuvant Atezolizumab Plus Chemotherapy Numerically Improves Survival in Early TNBC

May 12th 2023

The addition of atezolizumab to neoadjuvant chemotherapy generated numerical improvements in event-free survival, disease-free survival, and overall survival compared with chemotherapy plus placebo in patients with early-stage triple-negative breast cancer.

Sacituzumab Govitecan Produces Consistent Clinical Outcomes in mTNBC, Irrespective of Neutropenia and Diarrhea AEs

May 12th 2023

Sacituzumab govitecan-hziy produced comparable efficacy outcomes for patients with metastatic triple-negative breast cancer who had a higher incidence of grade 2 or 3 diarrhea and neutropenia vs patients in the overall population, according to a post hoc analysis of the phase 3 ASCENT trial presented at the 2023 ESMO Breast Cancer Annual Congress.

ER-low Expressors Experience Benefit With Trastuzumab Deruxtecan in DESTINY-Breast04 Subgroup Analysis

May 12th 2023

Fam-trastuzumab deruxtecan-nxki was associated with better efficacy outcomes compared with treatment of physician’s choice in patients with HER2-low, estrogen receptor-low metastatic breast cancer, according to findings from a subgroup analysis of the phase 3 DESTINY-Breast04 study.